Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:48 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Venrock Healthcare Capital Partners III, L.P. | 4,026,331 8.500% | 1,071,429 (+36.26%) | Filing History |
| 2024-11-14 5:46 pm Sale | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | RA Capital Management, L.P. | 1,061,233 2.200% | -1,061,232 (-50.00%) | Filing History |
| 2024-11-14 4:24 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Citadel Advisors LLC | 1,734,094 3.700% | 1,307,237 (+306.25%) | Filing History |
| 2024-11-14 4:15 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 3,202,798 6.800% | 1,071,429 (+50.27%) | Filing History |
| 2024-11-14 4:05 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Commodore Capital LP | 4,100,000 8.700% | 1,198,184 (+41.29%) | Filing History |
| 2024-11-13 5:55 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Polar Capital Holdings Plc | 2,687,797 5.690% | 2,687,797 (New Position) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | BlackRock Inc. BLK | 2,936,642 6.200% | 0 (Unchanged) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | BlackRock Inc. BLK | 2,936,642 6.200% | 2,936,642 (New Position) | Filing History |
| 2024-07-29 6:12 pm Sale | 2024-07-25 | 13D | ENLIVEN THERAPEUTICS INC ELVN | 5AM Ventures VI L.P. | 2,304,332 4.900% | -531,543 (-18.74%) | Filing History |
| 2024-05-20 4:55 pm Sale | 2024-05-16 | 13D | ENLIVEN THERAPEUTICS INC ELVN | ORBIMED ADVISORS LLC | 7,918,163 16.800% | -1,033,300 (-11.54%) | Filing History |
| 2024-04-15 7:21 pm Sale | 2024-04-11 | 13D | ENLIVEN THERAPEUTICS INC ELVN | 5AM Ventures VI L.P. | 2,835,875 6.100% | -1,000,100 (-26.07%) | Filing History |
| 2024-04-04 4:39 pm Purchase | 2024-04-02 | 13D | ENLIVEN THERAPEUTICS INC ELVN | ORBIMED ADVISORS LLC | 8,951,463 19.200% | 2,124 (+0.02%) | Filing History |
| 2024-02-16 4:15 pm Sale | 2024-02-14 | 13D | ENLIVEN THERAPEUTICS INC ELVN | 5AM Ventures VI L.P. | 3,835,975 9.300% | -825,000 (-17.70%) | Filing History |
| 2024-02-14 8:53 pm Purchase | 2023-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Venrock Healthcare Capital Partners III, L.P. | 2,954,902 7.200% | 740,760 (+33.46%) | Filing History |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Citadel Advisors LLC | 2,394,448 5.800% | 95,692 (+4.16%) | Filing History |
| 2024-02-14 4:05 pm Purchase | 2023-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Commodore Capital LP | 2,901,816 7.000% | 819,693 (+39.37%) | Filing History |
| 2024-02-14 3:45 pm Purchase | 2023-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 2,131,369 5.200% | 6,744 (+0.32%) | Filing History |
| 2024-02-14 3:31 pm Sale | 2023-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Pfizer Inc PFE | 389,429 0.950% | -1,168,293 (-75.00%) | Filing History |
| 2024-02-09 09:03 am Purchase | 2024-02-08 | 13G | ENLIVEN THERAPEUTICS INC ELVN | FMR LLC | 5,902,265 14.321% | 1,482,684 (+33.55%) | Filing History |
| 2024-02-07 12:16 pm Sale | 2023-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | BML Investment Partners, L.P. | 50,000 0.100% | -3,287,774 (-98.50%) | Filing History |